This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Dirithromycin" – news · newspapers · books · scholar · JSTOR(September 2014) (Learn how and when to remove this message)
Dirithromycin is a macrolide glycopeptide antibiotic.[1]
Dirithromycin (Dynabac) is a more lipid-soluble prodrug derivative of 9S-erythromycyclamine prepared by condensation of the latter with 2-(2-methoxyethoxy)acetaldehyde. The 9N, 11O-oxazine ring thus formed is a hemi-aminal that is unstable under both acidic and alkaline aqueous conditions and undergoes spontaneous hydrolysis to form erythromycyclamine. Erythromycyclamine is a semisynthetic derivative of erythromycin in which the 9-ketogroup of the erythronolide ring has been converted to an amino group. Erythromycyclamine retains the antibacterial properties of erythromycin oral administration. The prodrug, dirithromycin, is provided as enteric coated tablets to protect it from acid catalyzed hydrolysis in the stomach.
Orally administered dirithromycin is absorbed rapidly into the plasma, largely from the small intestine. Spontaneous hydrolysis to erythromycyclamine occurs in the plasma. Oral bioavailability is estimated to be about 10%, but food does not affect absorption of the prodrug.
^McConnell SA, Amsden GW (April 1999). "Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin". Pharmacotherapy. 19 (4): 404–15. doi:10.1592/phco.19.6.404.31054. PMID 10212011. S2CID 25018468.
Dirithromycin is a macrolide glycopeptide antibiotic. Dirithromycin (Dynabac) is a more lipid-soluble prodrug derivative of 9S-erythromycyclamine prepared...
Azithromycin – unique; does not extensively inhibit CYP3A4 Clarithromycin Dirithromycin – discontinued but was US FDA approved Erythromycin Not approved in...
P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin". British Journal of Clinical Pharmacology. 50 (4): 285–295. doi:10...
Dermatology Dupixent (Dupilumab), for eczema, marketed by Regeneron. Dynabac (Dirithromycin), for acute bacteria exacerbations. Sklice (Ivermectin), for head lice...